Antifibrotic Therapy in Idiopathic Pulmonary Fibrosis Candidates for Lung Transplantation Undergoing Pulmonary Rehabilitation

Overview

Journal J Bras Pneumol

Specialty Pulmonary Medicine

Date 2023 Feb 8

PMID 36753211

Authors

Monica Pruss Pereira

Gisele Branchini

Fernanda Bordignon Nunes

Stephan Altmayer

Guilherme Moreira Hetzel

Iveth Romero

Adalberto Sperb Rubin

Juliessa Florian

Douglas Zaione Nascimento

Guilherme Watte

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the impact of pulmonary rehabilitation (PR) on functional outcomes and health-related quality of life (HRQoL) in idiopathic pulmonary fibrosis (IPF) patients placed on a lung transplant waitlist and receiving antifibrotic therapy (AFT).

Methods: This was a retrospective observational study of consecutive IPF patients receiving AFT with either pirfenidone or nintedanib (the AFT group) and undergoing PR between January of 2018 and March of 2020. The AFT group and the control group (i.e., IPF patients not receiving AFT) participated in a 12-week PR program consisting of 36 sessions. After having completed the program, the study participants were evaluated for the six-minute walk distance (6MWD) and HRQoL. Pre- and post-PR 6MWD and HRQoL were compared within groups and between groups.

Results: There was no significant difference between the AFT and control groups regarding baseline characteristics, including age, airflow limitation, comorbidities, and oxygen requirement. The AFT group had a significant increase in the 6MWD after 12 weeks of PR (effect size, 0.77; p < 0.05), this increase being significant in the between-group comparison as well (effect size, 0.55; p < 0.05). The AFT group showed a significant improvement in the physical component of HRQoL at 12 weeks (effect size, 0.30; p < 0.05).

Conclusions: Among IPF patients undergoing PR, those receiving AFT appear to have greater improvements in the 6MWD and the physical component of HRQoL than do those not receiving AFT.

References

Caminati A, Lonati C, Cassandro R, Elia D, Pelosi G, Torre O . Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. Eur Respir Rev. 2019; 28(153). PMC: 9488913. DOI: 10.1183/16000617.0044-2019. View

Graney B, Lee J . Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Relat Outcome Meas. 2018; 9:321-328. PMC: 6163010. DOI: 10.2147/PROM.S144425. View

Chambers D, Cherikh W, Harhay M, Hayes Jr D, Hsich E, Khush K . The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38(10):1042-1055. PMC: 6816340. DOI: 10.1016/j.healun.2019.08.001. View

Pereira C, Baddini-Martinez J, Baldi B, Jezler S, Rubin A, Alves R . Safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis in Brazil. J Bras Pneumol. 2019; 45(5):e20180414. PMC: 8653976. DOI: 10.1590/1806-3713/e20180414. View

. Erratum: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015; 192(5):644. DOI: 10.1164/rccm.1925erratum. View

da Fontoura F, Cortozi Berton D, Watte G, Florian J, Schio S, Camargo J . Pulmonary Rehabilitation in Patients With Advanced Idiopathic Pulmonary Fibrosis Referred for Lung Transplantation. J Cardiopulm Rehabil Prev. 2018; 38(2):131-134. DOI: 10.1097/HCR.0000000000000315. View

Janssen K, Rosielle D, Wang Q, Kim H . The impact of palliative care on quality of life, anxiety, and depression in idiopathic pulmonary fibrosis: a randomized controlled pilot study. Respir Res. 2020; 21(1):2. PMC: 6942318. DOI: 10.1186/s12931-019-1266-9. View

Raghu G, Collard H, Egan J, Martinez F, Behr J, Brown K . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183(6):788-824. PMC: 5450933. DOI: 10.1164/rccm.2009-040GL. View

Raghu G, Remy-Jardin M, Myers J, Richeldi L, Ryerson C, Lederer D . Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018; 198(5):e44-e68. DOI: 10.1164/rccm.201807-1255ST. View

10.

Maher T, Strek M . Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019; 20(1):205. PMC: 6731623. DOI: 10.1186/s12931-019-1161-4. View

11.

Leuschner G, Stocker F, Veit T, Kneidinger N, Winter H, Schramm R . Outcome of lung transplantation in idiopathic pulmonary fibrosis with previous anti-fibrotic therapy. J Heart Lung Transplant. 2017; . DOI: 10.1016/j.healun.2017.07.002. View

12.

Baddini-Martinez J, Baldi B, Costa C, Jezler S, Lima M, Rufino R . Update on diagnosis and treatment of idiopathic pulmonary fibrosis. J Bras Pneumol. 2015; 41(5):454-66. PMC: 4635093. DOI: 10.1590/S1806-37132015000000152. View

13.

Hoffman M, Chaves G, Ribeiro-Samora G, Britto R, Parreira V . Effects of pulmonary rehabilitation in lung transplant candidates: a systematic review. BMJ Open. 2017; 7(2):e013445. PMC: 5294003. DOI: 10.1136/bmjopen-2016-013445. View

14.

Pellegrino R, Viegi G, Brusasco V, Crapo R, Burgos F, Casaburi R . Interpretative strategies for lung function tests. Eur Respir J. 2005; 26(5):948-68. DOI: 10.1183/09031936.05.00035205. View

15.

Campolina A, Ciconelli R . [SF-36 and the development of new assessment tools for quality of life]. Acta Reumatol Port. 2008; 33(2):127-33. View

16.

. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002; 166(1):111-7. DOI: 10.1164/ajrccm.166.1.at1102. View

17.

Wickerson L, Brooks D, Reid W, Singer L, Granton J, Mathur S . Exertional Oxygen Requirements During Exercise Training in Advanced Interstitial Lung Disease. J Cardiopulm Rehabil Prev. 2018; 38(6):419-424. DOI: 10.1097/HCR.0000000000000338. View

18.

Dowman L, Hill C, May A, Holland A . Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021; 2:CD006322. PMC: 8094410. DOI: 10.1002/14651858.CD006322.pub4. View

19.

Florian J, Watte G, Teixeira P, Altmayer S, Schio S, Sanchez L . Pulmonary rehabilitation improves survival in patients with idiopathic pulmonary fibrosis undergoing lung transplantation. Sci Rep. 2019; 9(1):9347. PMC: 6597536. DOI: 10.1038/s41598-019-45828-2. View

20.

Hanada M, Kasawara K, Mathur S, Rozenberg D, Kozu R, Hassan S . Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J Thorac Dis. 2020; 12(3):1041-1055. PMC: 7139046. DOI: 10.21037/jtd.2019.12.27. View